Tissue Regenix Group Plc
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal … Read more
Tissue Regenix Group Plc (TRX) - Total Liabilities
Latest total liabilities as of June 2025: GBX18.56 Million GBX
Based on the latest financial reports, Tissue Regenix Group Plc (TRX) has total liabilities worth GBX18.56 Million GBX as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tissue Regenix Group Plc - Total Liabilities Trend (2007–2024)
This chart illustrates how Tissue Regenix Group Plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tissue Regenix Group Plc Competitors by Total Liabilities
The table below lists competitors of Tissue Regenix Group Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
POU SHENG INTL
BE:P5C
|
Germany | €4.65 Billion |
|
Onion Global Limited
PINK:OGBLY
|
USA | $376.96 Million |
|
Amreli Steels Ltd
KAR:ASTL
|
Pakistan | PKRs27.11 Billion |
|
Integrated Micro-Electronics Inc
PSE:IMI
|
Philippines | ₱768.47 Million |
|
AEON STORES (HK)
MU:AVK1
|
Germany | €5.67 Billion |
|
HELMA EIGENHEIMBAU - Dusseldorf Stock Exchang
DU:H5E
|
Germany | €330.96 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Tissue Regenix Group Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tissue Regenix Group Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tissue Regenix Group Plc (2007–2024)
The table below shows the annual total liabilities of Tissue Regenix Group Plc from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX16.29 Million | +17.30% |
| 2023-12-31 | GBX13.89 Million | +6.83% |
| 2022-12-31 | GBX13.00 Million | +37.23% |
| 2021-12-31 | GBX9.47 Million | +6.63% |
| 2020-12-31 | GBX8.88 Million | +50.58% |
| 2019-12-31 | GBX5.90 Million | +15.85% |
| 2018-12-31 | GBX5.09 Million | -18.38% |
| 2018-01-31 | GBX6.24 Million | 0.00% |
| 2017-12-31 | GBX6.24 Million | +202.18% |
| 2016-12-31 | GBX2.06 Million | -25.95% |
| 2016-01-31 | GBX2.79 Million | +154.66% |
| 2015-01-31 | GBX1.09 Million | -39.87% |
| 2014-01-31 | GBX1.82 Million | +68.31% |
| 2013-01-31 | GBX1.08 Million | +6.17% |
| 2012-01-31 | GBX1.02 Million | +154.54% |
| 2011-01-31 | GBX400.37K | +683.16% |
| 2010-01-31 | GBX51.12K | -15.55% |
| 2009-01-31 | GBX60.53K | -27.52% |
| 2008-01-31 | GBX83.52K | +432.23% |
| 2007-01-31 | GBX15.69K | -- |